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Molecular Imaging of Activated 
Platelets Allows the Detection 
of Pulmonary Embolism with 
Magnetic Resonance Imaging
Timo Heidt1,*, Simon Ehrismann1,*, Jan-Bernd Hövener2,3, Irene Neudorfer1, Ingo Hilgendorf1, 
Marco Reisert2, Christoph E. Hagemeyer4, Andreas Zirlik1, Jochen Reinöhl1, Christoph Bode1, 
Karlheinz Peter5, Dominik von Elverfeldt2,# & Constantin von zur Muhlen1,#
Early and reliable detection of pulmonary embolism (PE) is critical for improving patient morbidity and 
mortality. The desire for low-threshold screening for pulmonary embolism is contradicted by 
unfavorable radiation of currently used computed tomography or nuclear techniques, while standard 
magnetic resonance imaging still struggles to provide sufficient diagnostic sensitivity in the lung. In this 
study we evaluate a molecular-targeted contrast agent against activated platelets for non-invasive 
detection of murine pulmonary thromboembolism using magnetic resonance imaging. By intravenous 
injection of human thrombin, pulmonary thromboembolism were consistently induced as confirmed by 
immunohistochemistry of the lung. Magnetic resonance imaging after thrombin injection showed local 
tissue edema in ⁎T2  weighted images which co-localized with the histological presence of pulmonary 
thromboembolism. Furthermore, injection of a functionalized contrast agent targeting activated 
platelets provided sensitive evidence of focal accumulation of activated platelets within the edematous 
area, which, ex vivo, correlated well with the size of the pulmonary embolism. In summary, we here 
show delivery and specific binding of a functionalized molecular contrast agent against activated 
platelets for targeting pulmonary thromboembolism. Going forward, molecular imaging may provide 
new opportunities to increase sensitivity of magnetic resonance imaging for detection of pulmonary 
embolism.
Pulmonary thromboembolism (PE) is a mayor burden of morbidity and mortality worldwide, especially, if 
detected late or not at all1,2. With an annual incidence of 100 to 200 cases per 100 000, venous thromboembolism 
constitutes the third most frequent cardiovascular disease in the Western world3,4.
Standard techniques for detection of pulmonary embolism involve contrast-enhanced computed tomography 
or ventilation-perfusion szintigraphy5,6. Both techniques have proven high sensitivity and specificity for detection 
of pulmonary embolism, but involve radiation, which is unfavorable in young patients or if the pre-test proba-
bility is low.
Although magnetic resonance imaging (MRI) would provide a radiation-free alternative to these conventional 
techniques7, susceptibility artifacts in the lung due to repeated tissue-air transitions challenge image quality and 
limit sensitivity especially for the detection of smaller thromboemboli8,9. As a consequence, MRI is not recom-
mended for detection of pulmonary embolism by current US or European guidelines10,11.
Molecular imaging with target specific imaging probes constitutes an emerging field because of its excel-
lent possibilities to facilitate highly selective detection of epitopes even at very low density or in sparse con-
trast regions. Thromboembolism are formed from a mixture of fibrin, coagulation factor-mediated peptides and 
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platelets. Among these, fibrin and alpha2-antiplasmin have previously been targeted in diverse formulations using 
gadolinium or perfluorocarbon compounds for contrast imaging and have shown promising results for the detec-
tion of venous thromboembolism12–14. With EP-2104R, fibrin-targeting has translated from bench to bedside, but 
a routine clinical application is still pending15.
Targeting platelets might be an additional strategy for the detection thromboembolism. We have previously 
described a single-chain antibody directed against the highly abundant ligand induced binding sites (LIBS) of 
the GPIIb/IIIa receptor which are specific for activated platelets16,17. Conjugated to microparticles of iron oxide 
(MPIO), this contrast agent has successfully been used for MRI-based detection of platelet activation in carotid 
thrombosis18.
In this study we investigate if targeting of activated platelets using MPIO-labeled single-chain antibodies can 
be used for the detection of murine pulmonary thromboembolism with magnetic resonance imaging.
Results
Experiments performed in the study were conducted in three experimental cohorts as specified in Fig. 1.
Intravenous injection of human thrombin induces pulmonary thromboembolism. To induce 
pulmonary embolism human thrombin was injected intravenously using a tail vein catheter. Slow injection 
ensured survival of approximately 80% of study animals (data not shown). Immunohistochemistry for the 
platelet-specific epitope CD41 was used to confirm thromboemboli in pulmonary vessels. Based on vessel size 
and degree of vessel obstruction pulmonary thromboembolism were graded in four different size categories 
(Fig. 2a). Thromboembolism with grades I through III were most frequent, while the incidence of very large pul-
monary thromboembolism (grade IV) was rare. In comparison, almost no thrombosis was found in pulmonary 
vessels of saline injected animals (Fig. 2b).
LIBS-MPIO selectively binds to activated platelets in pulmonary thromboembolism. We next 
applied LIBS-MPIO or Control-MPIO after 30 minutes following injection of human thrombin. Figure 3a shows 
activated platelets in pulmonary embolism and co-localization with presence of contrast agent (MPIO) after 
injection of labeled LIBS or Control single-chain antibody. At comparable amounts of pulmonary embolism after 
injection of human thrombin, LIBS contrast agent resulted in significantly higher MPIO target binding on throm-
boembolism compared to Control-MPIO (n = 6–8 mice per group, p < 0.05; Mann-Whitney U Test; Fig. 3b). 
Figure 1. Experimental setup. Experiments performed in the study were conducted in three experimental 
cohorts. (a) Experimental setup for data shown in Fig. 2. Lungs of mice intravenously injected with either 
thrombin or saline were harvested 30 minutes after injection. (b) Experimental setup for data shown in Fig. 3. 
Mice were intravenously injected with thrombin. 30 minutes after injection, mice received LIBS-MPIO or 
Control-MPIO contrast agent. After additional 30 min lungs were harvested. (c) Experimental setup for 
data shown in Figs 3c, 4 and 5. Mice received thrombin and after 30 minutes LIBS-MPIO or Control-MPIO 
contrast agent. Additional 30 minutes later magnetic resonance imaging was conducted. Directly after magnetic 
resonance imaging lungs were harvested for ex vivo analysis.
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Comparison of MPIO target binding to thromboembolism grade shows significant correlation for LIBS-MPIO 
(R2 = 0.94) compared to Control-MPIO (R2 = 0.34; n = 6 mice per group, p < 0.05, Pearson correlation; Fig. 3c).
Injection of human thrombin focally increases pulmonary signal in ⁎T2 - weighted MRI. 
Performing in vivo ⁎T2  weighted MRI in mice before and after injection of human thrombin, we found focal 
increase of ⁎T2  signal in 75% of thrombin injected animals as signs of segmental tissue edema around and subse-
quent of the obstructed vessel after thrombin injection. Of note, signal increase was not present in saline injected 
animals (Fig. 4a). Histology for platelet CD41 from resected lungs revealed that pulmonary embolism (GII-IV) 
correlated with areas of increased ⁎T2  signal (Fig. 4b), while only minor thromboembolism (GI) was found in 
areas without ⁎T2  increase.
MPIO contrast agent deposition can be detected within ⁎T2  positive segmental edema. After 
injection of human thrombin and acquisition of ⁎T2  weighted images, LIBS-MPIO or Control-MPIO contrast 
agent were injected intravenously. Injection of LIBS-MPIO was followed by a significant signal loss at the border 
of the edema compared to signal loss after injection of Control-MPIO (n = 6 mice per group, p < 0.05, 
Mann-Whitney U Test; Fig. 5a–c). Increased numbers of MPIO found in corresponding thromboembolism 
reflected this difference (n = 6 mice per group, p < 0.05, Mann-Whitney U Test; Fig. 5d).
Discussion
Pulmonary embolism is a major health burden responsible for considerable morbidity and mortality also in 
young patients. In the present study we applied a molecular-targeted contrast agent (LIBS-MPIO) towards accu-
mulation of activated platelets for highly sensitive, non-invasive detection of pulmonary embolism using mag-
netic resonance imaging in a murine model. Injection of human thrombin via a tail vein catheter in vivo resulted 
in formation of local pulmonary edema as described by gain of signal in ⁎T2  weighted MR images. Microparticles 
of iron oxide coupled to LIBS-single-chain antibody allowed for non-invasive detection due to a loss of signal 
within the edema while binding to activated platelets. Ex vivo, this was confirmed by showing specific binding of 
LIBS-MPIO to activated platelets. Histology showed the presence of thromboembolism within the representative 
pulmonary edema as well as specific deposition of microparticles of iron-oxide at the target of interest.
Figure 2. Grading of thrombin-induced pulmonary thromboembolism. (a) Grading of pulmonary 
embolism according to vessel size and degree of vessel obstruction (GI-IV). Small vessel (maximum 
diameter < 150 μ m: GI < 50% vessel obstruction, GII > 50% vessel obstruction) or large vessels (maximum 
diameter > 150 μ m: GIII < 50% vessel obstruction, GIV > 50% vessel obstruction). Bar indicates 50 μ m.  
(b) Mean number of pulmonary embolism per lobe after intravenous thrombin injection, overall and  
according to embolism grade compared to saline injection (n = 5 mice per group, Data are shown as 
mean ± s.e.m.; p < 0.05, Mann-Whitney U Test; ns = not significant).
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Molecular imaging for the detection of pulmonary embolism with magnetic resonance imaging has mainly 
focused on fibrin13,15,19,20. Besides fibrin, platelets have been shown to be another relevant component of PE21. 
The susceptibility to activation and tendency towards accumulation - once stimulated by other platelets, fibrin or 
clotting factors - makes platelets an ideal target for the detection of very small amounts of substrate.
Furthermore, besides aggregation, platelets also release vasoactive agents such as serotonin, prostaglan-
dins and thromboxane A2 which drive adverse vasoconstriction and pulmonary hypertension22. Additionally, 
microparticles from activated platelets are involved in vascular inflammation and coagulation23. Platelets thus 
are important not only for vessel obstruction, but also for subsequent vascular inflammation and pathogenesis 
following pulmonary embolism. Looking for alternative fields of application next to imaging pulmonary embo-
lism, targeting and imaging of activated platelets in the lung using magnetic resonance imaging could also be 
explored for imaging in pulmonary hypertension, pulmonary vascular inflammation and recurrent thrombotic 
vessel obstruction, too. To this end, we have previously demonstrated that targeting of activated platelets could be 
used for the detection of cerebrovascular or myocardial inflammation24,25.
Pulmonary embolism was induced using a tail vein catheter for injection of human thrombin, as previously 
described by Nagaschima et al.26 Compared to alternative vascular access routes, e.g. the jugular vein27, the remote 
location of the tail vein as compared to the lung is less likely to induce susceptibility artifacts. Furthermore, injec-
tion of human thrombin via the tail vein allowed for repetitive MR image acquisition before and after induction 
of pulmonary embolism without moving the animal in the MR scanner, thus reducing motion artifacts and pro-
viding excellent in-plane consistency of acquired images.
Injection of human thrombin resulted in pulmonary thrombi of different sizes as confirmed by immunohis-
tochemistry for platelet CD41. Mortality rate after injection of human thrombin was about 20%, well in line with 
Figure 3. LIBS-MPIO contrast agent specifically binds to activated platelets of pulmonary 
thromboembolism. (a) Immunohistochemistry staining for platelet CD41 in thrombin-induced pulmonary 
embolism (PE) after injection of LIBS-MPIO or Control-MPIO. ↘ MPIO visible as small spheres on the surface 
of CD41+ cells. Bar indicates 10 μ m. (b) Number of PE per left lung (left) after injection of human thrombin and 
LIBS-MPIO compared to thrombin and Control-MPIO Quantification of mean MPIO-binding per PE section 
(right) was performed by counting MPIO co-localized to CD41+ cells using light microscopy with 63x to 100x 
magnification. (n = 6–8 mice per group, p < 0.05; ns = not significant, Mann-Whitney U Test). (c) Correlation 
of PE grade with number of MPIOs bound to PE section after injection of LIBS-MPIO or Control-MPIO (n = 6 
mice per group, p < 0.05, Pearson correlation). Data are shown as mean ± s.e.m.
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previous reports14,26. Mortality is most likely due to the size of the PE with central vessel obstruction leading to 
fatal right-sided heart failure. This may explain why grade grade IV pulmonary embolism was a rare event in this 
experimental setup. As the lung is a highly vascularized organ, ex vivo histology of these mice for detection of 
such a fatal pulmonary thromboembolism failed due to post-mortem clotting artifacts. Comparing results after 
human thrombin injection to animals injected with saline, however, confirmed specificity of the human-thrombin 
approach for pulmonary embolism grades G II-IV.
Microparticles of iron oxide (MPIO) exert a very strong signal in magnetic fields surpassing their actual par-
ticle size approximately 50 fold, which allows for detection of very sparse target substrate. Visibility of MPIOs by 
light microscopy additionally facilitates detection and quantification of contrast agent binding ex vivo, as well as 
correlation with findings in MRI. Quantification of MPIOs per field of view in pulmonary embolism revealed a 
good correlation with embolism size. In a translational application, this would allow for non-invasive sizing and 
mapping of pulmonary embolism dissemination. Larger scale studies would need to evaluate if this information 
could be used as a prognostic marker.
A relevant limitation of the contrast agent used is that MPIOs impose their contrast as negative signal, caused 
by field disturbance of iron oxide particles and resulting in local signal loss in the area of contrast deposition28. 
Furthermore, the lung is a problematic organ for magnetic resonance imaging with ⁎T2  due to the high degree of 
phase transition between tissue and air also causing susceptibility artifacts. Therefore, despite the excellent sensi-
tivity, MPIOs may not seem ideal for application in the lung, at first sight.
In this model, injection of human thrombin caused an early and persistent, segmental signal gain in T2 and ⁎T2  
weighted images comparable to zones of pulmonary edema observed in humans in the setting of post-embolic 
pulmonary infarction29,30. Histology of the edematous pulmonary segments revealed presence of thromboembo-
lism in the corresponding area, while no relevant thrombus was observed in the absence of pulmonary edema. 
After injection of LIBS-MPIO contrast agent, the signal gain induced by the edema provided a background which 
allowed for sensitive detection of accumulation of activated platelets at the border of edematous zones demarcat-
ing the pulmonary embolism as focal zones of signal loss within the edema. While this phenomenon allowed for 
the use of MPIOs for target-contrast, smaller pulmonary embolism may not cause relevant pulmonary edema and 
therefore could escape detection despite proper target binding. Also, in humans, the presence of pulmonary 
Figure 4. Thrombin-induced pulmonary edema correlates with presence of thromboembolism. (a) In vivo 
⁎T2  weighted MRI of the thorax before (left) and after (right) intravenous injection of human thrombin. Green 
dotted line indicates area of ⁎T2  signal increase. Compared to saline injection, injection of human thrombin 
induced significant focal signal increase in ⁎T2  weighted images (saline n = 4-vs. thrombin n = 12 mice per 
group, p < 0.05, Mann-Whitney U Test). (b) Immunohistochemistry staining for platelet CD41 (20x 
magnification) in thrombin-induced pulmonary embolism (PE). Bar indicates 100 μ m. Relevant pulmonary 
embolism can be found in areas with increased ⁎T2 , but is absent in tissue without 
⁎T2  signal increase. Data are 
shown as mean ± s.e.m.
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edema is mostly seen in massive embolism which is challenging the accuracy of detection of smaller thromboem-
bolism. This may explain why in vivo the correlation between MRI signal and embolism size remains challenging 
notwithstanding promising ex vivo results.
A further limitation is that analyzing signal decay within a defined area with previous gain of signal requires 
that the signal loss reported refers to the entire edematous zone, instead of the thromboembolism only. Therefore, 
the local signal reported is most likely to be underestimated and true local changes might be more pronounced.
Taking these limitations into account, this murine study provided evidence that platelets are a suitable tar-
get for detection of pulmonary embolism with molecular imaging. Animal models with less edema formation, 
which might be caused by missing collateralization of the pulmonary circulation in murine models, will need to 
confirm the obtained data. Furthermore, evaluation of positive contrast agents as has been shown for gadolinium 
could overcome the technical need for background edema13. Alternatively, accumulation of 19-Fluor in vascular 
thrombosis has been shown to give sufficient signal for non-invasive detection with MRI14. Also, biocompatible 
magnetoliposomes loaded with contrast agent could overcome toxicity concerns of MPIOs31. Ultimately, transfer 
studies involving human patients will have to show if sensitivity and specificity of this approach is suitable for 
future clinical applications.
Figure 5. Contrast agent-induced signal voids can be detected within edematous area. (a) In vivo ⁎T2  
weighted MRI of the thorax after intravenous application of human thrombin (left panel) and injection of 
Control-MPIO (right panel, above) or LIBS-MPIO (right panel below). Right panel show extracted overlay of 
edema (gray zone) and MPIO-induced signal decay within this area (pseudo-colored pink-yellow). Below, 3D 
map of edema after thrombin and corresponding signal overlay after injection of LIBS-MPIO in the murine 
lung. (b) Edema area after thrombin injection in LIBS-MPIO or Control-MPIO group does not differ (6 mice 
per group, ns = not significant). (c) Percent change of signal intensity in human thrombin-induced edema after 
injection of LIBS-MPIO or Control-MPIO (n = 6 mice per group, p < 0.05, Mann-Whitney U Test). (d) Mean 
number of MPIO found per immunohistochemistry section of pulmonary embolism after ex vivo preparation 
and staining for platelet CD41 (n = 6 per group, p < 0.05, Mann-Whitney U Test). Data are shown as 
mean ± s.e.m.
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Conclusions
To our knowledge, this is the first study investigating the detection of pulmonary embolism via targeting acti-
vated platelets with molecular magnetic resonance imaging. The involvement of activated platelets in formation 
of thromboemboli by aggregation as well as pulmonary vascular pathophysiology via platelet-induced vascular 
inflammation, makes selective imaging of activated platelets an attractive target with possible future application in 
clinical diagnostics as well as basic research on pulmonary vascular disease. In this study we show that activated 
platelets in pulmonary embolism can be detected non-invasively by magnetic resonance imaging. Persistent limi-
tations request further studies and evaluation of different MR-suitable contrast agents to evaluate its use for future 
clinical application. Radiation-free assessment of pulmonary embolism combined with anatomical and func-
tional information would add great value as compared to existing computed tomography or ventilation-perfusion 
scintigraphy and might be helpful for the physician in guiding the patient.
Methods
Animals. Female C57BL/6N mice, age 10–12 weeks, were purchased from Charles River Laboratories 
(Sulzfeld, Germany). Mice were housed in cages of 5 animals. Chow and water was provided without restriction. 
The numbers of animals used for each study group are indicated in the figure legends. All experimental proto-
col were approved by the ethics committee of Freiburg University and the regional council of Freiburg, Baden-
Wuerttemberg, Germany: licence number 35-9185.81/G-13/120). Experiments were conducted in accordance 
with FELASA, GV-SOLAS standards for animal welfare.
Model of murine thrombin-induced pulmonary embolism. Pulmonary embolism was induced as 
previously described by Nagaschima et al.26 Prior to the induction of pulmonary embolism, mice were anesthe-
tized by subcutaneous injection of a mixture containing ketamine (250 mg/kg bw) and xylazine (12.5 mg/kg bw). 
Thereafter, a tail vein catheter was placed. Human thrombin (Thromborel S, Bayer, Germany) was slowly injected 
in a total volume of 100 μ l saline at a final concentration of 2500 Units per kg bw. Thrombin injection resulted in 
an approximate survival rate of 80%.
Platelet specific single-chain antibody (LIBS-MPIO). Monoclonal anti-LIBS single-chain antibody 
selectively binds to ligand-induced binding sites which are exposed on the activated glycoprotein IIb/IIIa recep-
tor, but are not exposed on resting platelets32. Single-chain antibody cloning, production and purification was 
performed as previously described33. A non-binging control single-chain antibody was constructed by amino 
base exchange. For MPIO-labeling, cobalt-functionalized auto-fluorescent MPIOs with a diameter of 1 μ m were 
conjugated to the histidine-tag of the LIBS/control single-chain antibody according to the manufacturer’s instruc-
tion (Dynal Biotech, Oslo, Norway). LIBS-single-chain antibody conjugated to MPIO will be called “LIBS-MPIO” 
contrast agent. Conjugation to unspecific control single-chain antibody will be referred to as “Control-MPIO” 
contrast agent.
Contrast agent injection. Contrast agents were injected at 0.5 mg/kg body weight in 100 μ l PBS using a 
tail vein catheter (80 cm length), 30 minutes after induction of pulmonary embolism to ensure enough time for 
thrombus formation. Imaging was performed 30 minutes after contrast agent injection to reduce unspecific bind-
ing properties and increase specificity.
Magnetic Resonance Imaging. All magnetic resonance experiments were performed on a dedicated small 
animal MRI system (BioSpec94/20, Bruker Germany), run with AVANCE III electronics, Paravision 5.1 software, 
and employing a quadrature whole body mouse birdcage resonator (id: 36 mm).
After induction of anesthesia and catheter placement in the tail vein, animals were placed head first in supine 
position onto the animal bed with a breathing sensor pad beneath the animal. Animal temperature was main-
tained by warm-water supported heating of the animal bed. During MRI, anesthesia was maintained via isoflu-
rane in O2 in a range of 0,8–1.8 Vol%, stabilizing the animals at a breathing rate of approximately 70 breaths per 
minute.
Imaging the lung all MRI protocols where retrospectively gated Intragate-FLASH sequences in order to main-
tain a breathing-rate independent signal steady state and therefore a constant image contrast.
A multislice pilot scan was performed in order to verify the animal position and to plan the main sequences. A 
2D multislice Intragate FLASH covering the complete lung, once in coronal and once in axial orientation was run 
three times. The scans where repeated once as a baseline, once after administration of thrombin, and once after 
administration of LIBS-MPIO. The intragate scans had a TE/TR of 1.39 ms/106 ms, 50 repetitions, a flip angle of 
15°, a resolution of 113 μ m in plane at a slice thickness of 400 μ m, and a total acquisition time of 11′ 22′ ′ per scan.
Image Analysis. Analysis of the images that were acquired (1) native, (2) 10 min post thrombin injection and 
(3) 30 min post LIBS-MPIO or LIBS-Control agent injection was performed using a custom-made software 
(Matlab, The Mathworks, USA). To compensate for motion and misalignment that occurred over the time span 
of the scans (120 min), each slice in datasets 1–3 was subjected to a non-rigid transformation to match a slice that 
was the sum of all three.
Edema was defined in the post-thrombin images (2) by a gain in signal of more than 50% with respect to the 
naive image for groups of ten or more connected voxels in each slice. The volume of the edema was quantified by 
counting these voxels across all slices. Areas clearly outside of the lung that showed an increased signal i.e. due to 
motion artifacts or misalignments were discarded manually.
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Within the area of an edema, the effect of the contrast agent was quantified by the total change in signal, i.e. 
the sum of signal intensities within the edema in post-thrombin images (2) compared to the sum in post-agent 
images (3).
For presentation, the edema area as well as the color-coded change in signal was superimposed on the ana-
tomical images post-thrombin (2).
Preparation of tissue for cryosection. For tissue preparation, mice where perfused with 10 ml of PBS in 
deep anesthesia via the right ventricle to clear pulmonary vessels from remnant blood. Afterwards Tissue-Tek 
embedding medium OCT (Sakura Finetek, Netherlands) diluted 1:3 parts with PBS was instilled into lungs via 
tracheal injection. Lungs where fully embedded in OCT and shock-frozen on dry ice. Tissue blocks where sec-
tioned with 10 μ m thickness at 30 μ m intervals and fixed using acetone.
Histology. Platelets were stained using a rat anti-mouse CD41 antibody (GTX 76011, GeneTex, Irvine/CA, 
USA) or unspecific control IgG1 isotype (MCA1211, Serotec, Puchheim, Germany). For secondary staining a 
biotinylated rabbit anti-rat IgG (BA-4001, Vector, Burlingame/CA, USA) was used. Afterwards, alkaline phos-
phatase and substrate kit (AK-5000 & SK-5100; Vector, Burlingame/CA, USA) after levamisol pre-treatment 
(X3021, DAKO, Hamburg, Germany) was applied for antibody detection. Sections were then embedded in 
Kaiser’s Glyceringelatine (1092420100, Merck, Hamburg, Germany). Due to their size (1 μ m), MPIO beads are 
visible using 63x magnification without further staining. MPIOs were quantified as mean number of MPIOs of 3 
sections per section at 63x magnification.
Histology sections were analyzed using a light microscope (Zeiss optics, Germany). Pulmonary embolism 
was quantified as mean of 3 representative sections of the according. Pulmonary emboli were graded according 
to size of obstructed vessels: small vessel (maximum diameter < 150 μ m: GI < 50% vessel obstruction, GII > 50% 
vessel obstruction) or large vessels (maximum diameter > 150 μ m: GIII < 50% vessel obstruction, GIV > 50% 
vessel obstruction).
Statistics. Statistical analyses were supported by GraphPad Prism software (GraphPad Software, Inc.). Results 
are depicted as mean ± standard error of mean if not stated otherwise. For two-group comparison, students t-test 
was applied if the pre-test for normality (D’Agostino-Pearson normality test) and equality of variances (Bartlett’s 
test) was not rejected at 0.05 significance level, otherwise a Mann-Whitney U test for nonparametric data was 
used. For a comparison of more than two groups an ANOVA, followed by a Bonferroni test for multiple compar-
ison, was applied. P values of p < 0.05 indicate statistical significance.
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